Mastercard won a New York BitLicense on May 27, giving it regulated footing to expand stablecoin and tokenized‑payment services under state supervision.

Cette AI founder Michael LaFave alleges Voya Financial accessed his devices, stole code and tracked him, a New York lawsuit says.

Chicago's Architect is pushing exchange‑traded futures on GPU and DRAM prices, setting up competition with CME and ICE. The move could make compute costs a tradable asset.

An experimental drug called bepirovirsen produced durable 'functional cures' in roughly 20% of patients in large trials, offering a potential finite therapy for chronic hepatitis B.

Modelers have removed the extreme RCP8.5/SSP5‑8.5 marker from the CMIP7 design; the revision narrows the upper‑end of projections but still leaves large warming and financial risk.

The Commerce Department unveiled a $2B CHIPS‑funded quantum package that includes $1B for IBM’s new foundry and minority equity stakes in several startups.

NYC‑based Runway hit No. 45 on CNBC's Disruptor 50 after a $315M Series E and major product and compute moves that pushed its valuation toward $5.3B.

A new Frontiers study finds a small uptick in lung cancer incidence after COVID‑19, especially among current and former smokers, and points to the enzyme TYMP as a likely mechanism.

New York’s cannabis regulator has launched a pilot observational study testing oral THC and CBD for adults with inflammatory bowel disease, partnering with licensed dispensaries.

A PLOS ONE study traced a 2020 apartment outbreak to shared bathroom ducts and urges retrofits — exhaust fans and non‑return flaps — to reduce airborne spread.

Goldman Sachs' operations chief says the bank will build a 'digital factory floor' of AI agents to automate back‑office work while saying overall headcount should stay largely unchanged.

A Lancet‑published consensus has renamed PCOS to PMOS to emphasize hormonal and metabolic causes. Patient groups are split as the three‑year roll‑out begins.

Mounjaro's Q1 sales topped Keytruda, lifting Lilly's revenue and reshaping the blockbuster drug ranking.